Attralus is a biopharmaceutical company focused on creating medicines to improve the lives of patients with systemic amyloidosis. The company uses pan-amyloid removal (PAR) therapeutics to bind and remove toxic amyloid in organs and tissues.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/06/2024 | Series B | $172.6MM | $xx.xx | $428.81MM | Logos Capital, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, venBio Partners, Alpha Wave Ventures, Bristol Myers Squibb | |
Price per Share
$xx.xx
Shares Outstanding
22,242,245
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Logos Capital, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, venBio Partners, Alpha Wave Ventures, Bristol Myers Squibb
|
||||||
09/14/2020 | Series A | $25.95MM | $xx.xx | $47.18MM | venBio Partners | |
Price per Share
$xx.xx
Shares Outstanding
17,347,691
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
venBio Partners
|